Evaluation of serum salusin-α and β levels in patients with obstructive sleep apnea.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI:10.1080/17520363.2024.2366151

Buğra Kerget, Dursun Erol Afşin, Esra Laloglu

引用次数: 0

Abstract

Aim: Salusin-α and salusin-β peptides are crucial in the development of cardiovascular diseases like coronary artery disease (CAD). This study compared serum levels of these peptides in patients with obstructive sleep apnea (OSA), those with both OSA and CAD.Materials & methods: Patients without OSA were included in Group 1, those with OSA alone comprised Group 2, and those with OSA and CAD were in Group 3.Results: Salusin-α level was significantly higher in controls than in Groups 2 and 3, while salusin-β levels were significantly higher in Groups 2 and 3 compared with the control group.Conclusion: Salusin-α and -β levels may be parameters that can guide the diagnosis of OSA in patients with a consistent clinical history.

查看原文本刊更多论文

评估阻塞性睡眠呼吸暂停患者的血清黄豆素-α 和 β 水平。

目的：Salusin-α 和 Salusin-β 肽对冠状动脉疾病（CAD）等心血管疾病的发展至关重要。本研究比较了阻塞性睡眠呼吸暂停（OSA）患者、同时患有 OSA 和 CAD 的患者血清中这两种肽的水平。材料和方法：无 OSA 患者为第一组，仅有 OSA 的患者为第二组，有 OSA 和 CAD 的患者为第三组。结果对照组的距蛋白-α水平明显高于第 2 组和第 3 组，而第 2 组和第 3 组的距蛋白-β水平明显高于对照组。结论距蛋白-α和-β水平可能是指导临床病史一致的患者诊断 OSA 的参数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.